Metabolic reprogramming in renal cancer: Events of a metabolic disease

Area of Science:

• Oncology
• Cancer Metabolism
• Molecular Biology

Background:

• Tumors reprogram nutrient uptake and metabolism to meet cancer cell demands.
• Metabolic reprogramming is driven by tumor suppressor gene loss and oncogene activation.
• Renal cell carcinoma (RCC) exhibits significant metabolic pathway alterations, earning it the name "metabolic disease".

Purpose of the Study:

• To detail the metabolic reprogramming in renal cell carcinoma (RCC).
• To identify key molecular players driving metabolic changes in RCC.
• To explore the therapeutic and diagnostic potential of understanding RCC metabolism.

Main Methods:

• Review of recent studies on cancer metabolic reprogramming.
• Analysis of key genetic and pathway alterations in RCC metabolism, including VHL gene inactivation and Ras-PI3K-AKT-mTOR pathway activation.
• Examination of the roles of Hypoxia-inducible factor (HIF) and Myc in RCC metabolic reprogramming.

Main Results:

• Metabolic reprogramming is a hallmark of cancer, essential for altered cellular requirements.
• In RCC, metabolic reprogramming is largely driven by von Hippel-Lindau (VHL) gene inactivation and Ras-PI3K-AKT-mTOR pathway activation.
• Key metabolic pathways, including glucose, fatty acid, glutamine, tryptophan, and arginine metabolism, as well as the tricarboxylic acid (TCA) cycle, are reprogrammed in RCC.

Conclusions:

• Understanding metabolic reprogramming in RCC provides insights into tumor growth and oncogenesis.
• Detailed knowledge of these metabolic shifts opens avenues for novel therapeutic targets and strategies.
• Metabolic reprogramming in RCC offers opportunities for biomarker discovery and improved tumor detection methods.